MedTrace Logo

Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound

NCT03829618 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2021-10-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess if there is decrease in cough during flexible bronchoscopy and endobronchial ultrasound when different modes of lidocaine administration are used. The modes of administration being evaluated are topical, nebulized and atomized.

Conditions

  • Bronchiectasis Adult
  • Mediastinal Lymphadenopathy
  • Pneumonia
  • Chest--Diseases
  • Infiltrates
  • Bronchopulmonary Disease
  • Cancer, Lung

Interventions

DRUG

Topical lidocaine

1% lidocaine topically applied in 4 mL aliquots

DRUG

Nebuliser solution

2% lidocaine dose at 2 mg/kg (max 160 mg) applied via jet nebulizer

DRUG

Nebuliser Suspension

2% lidocaine dosed at 2 mg/kg (max 160 mg) applied via vibrating mesh nebulizer

Sponsors & Collaborators

  • Milton S. Hershey Medical Center

    lead OTHER

Principal Investigators

  • Jennifer Toth · Milton S. Hershey Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2020-08-31
Completion
2020-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03829618 on ClinicalTrials.gov